TICKERNERD
Menu
ENVBENVBHealthcare · Biotechnology

ENVB Stock Forecast: Enveric Biosciences, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.41
−1.40% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$6.4M
Ticker Nerd rank
20 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−4.7%
1M
+9.3%
YTD
−61.2%
1Y
−90.4%
From 52W high
−91.9%
From 52W low
+11.0%
$1
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENVB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enveric Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
64
Volatility
61
Accruals
50
Momentum
26
Revisions
25
Issuance
23
Quality
14
Value
5

Size (95): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENVB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENVB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26ENVB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Mar 2025HC Wainwright & Co.ReiteratesBuy$10
30 Jan 2024HC Wainwright & Co.InitiatesBuy—
1 June 2022Alliance Global PartnersInitiatesBuy$1.25
8 Mar 2022Aegis CapitalDowngradeHold$7.00 → $0.20
8 July 2021Aegis CapitalInitiatesBuy—
28 June 2021Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENVB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ENVB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Enveric Biosciences, Inc. (ENVB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 88% of US stocks

EV / EBITDA
0.2×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−170.0%

Higher than 8% of US stocks

Return on assets
−87.3%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ENVB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENVBEnveric Biosciences, Inc.$6.4M
20
CDIOCardio Diagnostics Holdings, Inc.$6.0M
19
KAPAKairos Pharma Ltd.$6.9M
38
LIMNLiminatus Pharma, Inc.$6.9M
10
CLGNCollPlant Biotechnologies Ltd.$5.9M
35
NIKINiki Biosolutions, Inc.$7.0M
12
BOLTBolt Biotherapeutics, Inc.$7.0M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enveric Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENVB news & analysis

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Business Wire · 14 Aug 2026positive

Enveric Biosciences reported its financial results for the second quarter ended June 30, 2026, and provided a comprehensive corporate update. The company's CEO highlighted important progress made during the quarter on activities supporting its planned first-in-human clinical trial of its next-generation neuroplastogenic small molecules.

Why it matters — An Enveric watcher would care because the corporate update signals continued advancement of the company's pipeline toward a key first-in-human clinical milestone.

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Benzinga · 5 Aug 2026positive

Enveric Biosciences announced new preclinical data confirming that its lead psychiatric candidate, EB-003, maintains a non-hallucinogenic profile.

Why it matters — The data strengthens the differentiation of Enveric's lead candidate, which could be important for investors tracking its progress toward potential psychiatric treatments without hallucinogenic side effects.

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Business Wire · 5 Aug 2026positive

Enveric Biosciences announced new preclinical data from testing its lead candidate EB-003 using a GloSensor cAMP assay, which the company says supports evidence that the drug has a non-hallucinogenic profile.

Why it matters — For ENVB watchers, this data strengthens the case for EB-003 as a potential treatment for psychiatric disorders without the hallucinogenic side effects associated with other psychedelic-derived therapies.

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Business Wire · 28 July 2026positive

Enveric Biosciences (NASDAQ: ENVB) expressed support for the U.S. Food and Drug Administration's newly released final guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

Why it matters — The FDA guidance provides a clearer regulatory framework for Enveric's development of neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders.

FAQ

Frequently asked questions about ENVB stock

Is ENVB stock a buy right now?

Of the 1 analysts covering Enveric Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enveric Biosciences, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENVB?

As at 22 Aug 2026, Enveric Biosciences, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the ENVB stock forecast for 2030?

No analyst covering Enveric Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENVB are extrapolating price history, which says nothing about the business.

How has ENVB stock performed over the past year?

Enveric Biosciences, Inc. returned -90.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enveric Biosciences, Inc. do?

Enveric Biosciences Inc. is a biotechnology company primarily focused on developing novel small-molecule therapeutics for the treatment of cancer and neurological diseases.

What is the latest news on ENVB?

The most recent item we track (Business Wire, 14 Aug 2026): "Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026". Enveric Biosciences reported its financial results for the second quarter ended June 30, 2026, and provided a comprehensive corporate update. The company's CEO highlighted important progress made during the quarter on activities supporting its planned first-in-human clinical trial of its next-generation neuroplastogenic small molecules.

Company

About Enveric Biosciences, Inc.

Enveric Biosciences Inc. is a biotechnology company primarily focused on developing novel small-molecule therapeutics for the treatment of cancer and neurological diseases. By leveraging advanced technologies, the company aims to address unmet medical needs through innovative pharmaceutical approaches. Enveric Biosciences engages in preclinical research that incorporates cutting-edge techniques in medicinal science, focusing particularly on indications with high demand for new therapeutic options. The company's portfolio includes both proprietary and partnered drug candidates, advancing through various stages of clinical development. As part of the healthcare sector, Enveric Biosciences plays a crucial role in the broader effort to discover and develop new treatments that can significantly improve patient outcomes. Though in early stages of development, the company’s potential contributions to biotech innovation underscore its role in driving forward progress in medical research and drug discovery within the financial markets. Based in North America, Enveric pursues collaborations with various research institutions and biotech companies to enhance its drug development processes.

CEO Dr. Joseph Edward Tucker Ph.D. · 5 employees · United States · https://www.enveric.com